Clovis Oncology jumps on drug data from ovarian cancer study

Clovis Oncology

31/03/2022 11:36

** Shares of Clovis Oncology  CLVS.O  rise 38.7% to $2.29
premarket
    ** Co says its drug, Rubraca, improved the time newly
diagnosed advanced ovarian cancer patients survived without
their disease progressing compared to placebo in a late-stage
trial (https://refini.tv/36Neakm)
    ** The U.S. FDA in May 2020 approved Rubraca for the
treatment of adult patients with metastatic castration-resistant
prostate cancer, whose tumors have BRCA mutation
    ** Company plans to submit application to U.S. FDA during Q2
2022 for U.S. label expansion; European submission to follow
during Q3 2022
    ** Rubraca is also approved in the U.S. as a maintenance
treatment for adults with ovarian, fallopian tube, primary
peritoneal cancers, whose disease has returned and whose tumors
have responded to a platinum-based chemotherapy
    ** CLVS down ~39.11% YTD

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))